Otolaryngology Clinical Trials

Our Clinical Trials

The following is a list of the ongoing clinical trials in the department of Otolaryngology-Head & Neck Surgery. If you are interested in learning more about a trial, or would like to be a participant in the trial, please contact the trial coordinator at the number or email listed. If you have questions about our research or a clinical trial, please contact us the . Each division may have ongoing clinical trials. This page is kept up to date, but trials may close with little or no notice. 

Click on the Division noted below to jump to the clinical trials that are ongoing for that group:

Pediatric Clinical Trials

The Pediatric Division of the Department of Otolaryngology-Head & Neck Surgery is currently working on the following clinical trials:

  • Genetics of ear infections (otitis media)
  • Outcomes of procedures for laryngeal cleft repair for pediatric patients with dysphagia
  • Outcomes of tympanostomy tubes for patients with Down syndrome
  • Treatment outcomes in children with hypernasal speech (velopharyngeal insufficiency)
  • How children's ears are affected by cleft palate

If you are interested in finding out more about any of these studies, or if you are interested in participating in one of these studies, please call 503 494-5350 to schedule a consultation with either Dr MacArthur or Dr Milczuk in our Pediatric Otolaryngology clinic. If you would like to know if you are eligible to participate in a study, please email

Oregon Sinus Center

Title: Determinants of Medical and Surgical Treatment Outcomes in Chronic Sinusitis

Dates: 4/1/2011-6/30/2017

Source: National Institute on Deafness and Other Communication Disorders

Description: A multi-institutional prospective cohort study to compare quality of life outcomes between medical management and endoscopic sinus surgery for chronic rhinosinusitis. A total of 976 patients will be enrolled at several tertiary care centers around the country and coordinated at OHSU. This study also evaluates olfactory function, as well as cellular and molecular expression of patients with chronic sinus disease.

Role: Dr. Timothy L. Smith. Principal Investigator

Enrollment: OHSU is the coordinating research center and all enrollment activities take place within the Oregon Sinus Center at the Center for Health and Healing during normal clinic visits by invitation only. To date, other patient enrollment sites include the Medical University of South Carolina, University of Utah, and Stanford University.

Contact: or , Research Coordinator


Return to the top of the page

Head & Neck Surgery / Cancer Clinical Trials

  • RTOG 0920 (IRB 6918) - The purpose of this study is to investigate the effects of treatment with radiation therapy or radiation therapy plus the chemotherapy drug cetuximab, when given after surgery in patients with locally-advanced head and neck cancer.
  • Steroid Therapy After TORS (IRB #8071) – This study is being done to determine whether steroid treatment (dexamethasone) can help manage pain and improve swallowing function following transoral robotic surgery (TORS) for head and neck cancer. 
  • VTE2 (IRB #9434) – The purpose of this study is to determine whether the routine use of lovenox (a blood thinner) reduces the incidence of blood clots (venous thromboembolism or VTE) in the legs of head and neck cancer patients after surgery.
  • Galera GT-201 (IRB#15152) - The purpose of this study is to investigate the ability of a new drug (GC4419) to prevent soreness and inflammation in the mouth and throat in patients undergoing radiation treatment for certain head and neck cancers.

If you are interested in getting more information about, or participating in, the Head & Neck Surgery / Cancer Clinical trials, email or call at 503 494-5355.


Return to the top of the page

Otology Clinical Trials

Title: Fludrocortisone for Sudden Hearing Loss (IRB 6240)

Description: The purpose of this study is to test whether fludrocortisone (a synthetic version of the natural hormone aldosterone) can treat sudden hearing loss within three months of its onset when another steroid has failed.